Visual Field Defects, Visual Field Loss
Conditions
Keywords
visual field defect, visual restoration therapy
Brief summary
The goal of this clinical trial is to learn if visual restoration therapy (VRT) (a type of treatment that aims to improve vision) works to the visual rehabilitation of patients with visual field defects. It will also learn about the safety of VRT. The main questions it aims to answer are: * Can visual reconstruction therapy help expand the visual field in patients with visual field defects? * What medical problems do patients with visual field defects experience during the procedure of VRT? Researchers will look at how patients with visual field defects who use a visual aid in combination with VRT and those who use a visual aid only, compare the visual field expansion at three months to see how well visual reconstruction therapy works. Participants will: * will undergo a specialized visual function assessment and be provided with a pair of appropriate vision aids. * Visit the clinic at one month and three months after enrolment for review of visual function and completion of a Chinese-version Low Vision Quality of Life (CLVQOL) questionnaire. * Participants receiving VRT will additionally undergo 30 minutes of VRT three times per week for 3 months. * Keep a diary for their symptoms and severity and frequency of occurrence during treatment.
Interventions
BEHAVIORALvisual restoration therapy
In this study, we used a reversing checkerboard pattern as a stimulus and acted on the relatively dark spots area of the patient's visual field.
Sponsors
Xuanwu Hospital, Beijing
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
1. Participants with a clear diagnosis of visual field defects. 2. Participants were between 18 and 80 years of age (including borderline values); 3. Participants have been treated for their primary disease and conditions are stable; 4. Participants are not at significant risk of vision loss in the last three months; 5. Participants do not have planned intraocular surgery during the trial period； 6. Participants can understand the trial protocol and sign informed consent.
Exclusion criteria
1. Participants diagnosed as blindness; 2. Participants with a previous history of seizures or other psychiatric disorders; 3. Participants with cognitive impairments; 4. Participant's attention span is less than 30 minutes; 5. Participants had conditions such as significant ptosis or severe dry eye; 6. Participants who were in poor general health or who could not cooperate in completing the study protocol for some reasons such as transport.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| visual field mean deviation (MD) value | A total of 3 examinations were performed during the trial: before treatment, after 1 month of treatment, and after 3 months of treatment. | using the Humphrey Field Analyzer 30-2 test to obtain MD values |
Contacts
Primary ContactZhen Li, MD. and PHD.
Outcome results
None listed